Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
. 2023;23(1):e190622206159.
doi: 10.2174/1871526522666220619121539.

MMP3 in Severe COVID-19: A Biomarker or Therapeutic Target?

Sultan Almuntashiri  1 , Duo Zhang  1 , Payaningal R Somanath  1 , Andrea Sikora  1
Affiliations

MMP3 in Severe COVID-19: A Biomarker or Therapeutic Target?

Sultan Almuntashiri et al. Infect Disord Drug Targets. 2023.

Abstract

Identifying novel therapies is a critical need in the treatment of coronavirus disease-19 (COVID-19) and acute respiratory distress syndrome (ARDS). Stromelysin-1, also known as matrixmetalloproteinase 3 (MMP3), has been investigated as a diagnostic biomarker and a potential pharmacological target. Here, we discuss the recent findings of Gelzo et al. in the context of additional MMP3 investigations to delineate its exact role in diagnosis, prognostication, and phenotyping, in addition to its promising role as a therapeutic target in COVID-19-associated respiratory failure.

Keywords: ARDS; Biomarker; MMP3; potential pharmacological target; respiratory failure; therapeutic target.

PubMed Disclaimer

Conflict of interest statement

CONFLICT OF INTEREST

The authors declare no conflict of interest, financial or otherwise.

Comment on

  • Infect Disord Drug Targets.

Similar articles

See all similar articles

Cited by

References

    1. Gelzo M; Cacciapuoti S; Pinchera B; De Rosa A; Cernera G; Scialo F; Comegna M; Mormile M; Fabbrocini G; Parrella R Matrix metalloproteinases (MMP) 3 and 9 as biomarkers of severity in COVID-19 patients. Sci Rep, 2022, 12, 1212. 10.1038/s41598-021-04677-8 - DOI - PMC - PubMed
    1. Artham S; Verma A; Newsome AS; Somanath PR Patients with acute respiratory distress syndrome exhibit increased stromelysin1 activity in the blood samples. Cytokine, 2020, 131, 155086. 10.1016/j.cyto.2020.155086 - DOI - PMC - PubMed
    1. Artham S; Gao F; Verma A; Alwhaibi A; Sabbineni H; Hafez S; Ergul A; Somanath PR Endothelial stromelysin1 regulation by the forkhead box-O transcription factors is crucial in the exudative phase of acute lung injury. Pharmacol. Res, 2019, 141, 249–263. 10.1016/j.phrs.2019.01.006 - DOI - PMC - PubMed
    1. Characterisation WHOWGC A minimal common outcome measure set for COVID-19 clinical research. Lancet Infect. Dis, 2020, 20(8), e192–e197. 10.1016/S1473-3099(20)30483-7 - DOI - PMC - PubMed
    1. Matthay MA; Zemans RL; Zimmerman GA; Arabi YM; Beitler JR; Mercat A; Herridge M; Randolph AG; Calfee CS Acute respiratory distress syndrome. Nat. Rev. Dis. Primers, 2019, 5(1), 18. 10.1038/s41572-019-0069-0 - DOI - PMC - PubMed

MeSH terms